Sphingomyelin synthase as a potential target for D609-induced apoptosis in U937 human monocytic leukemia cells

Experimental Cell Research

Volumn 292, Issue 2, 2004, Pages 385-392

  Meng, Aimin ^a   Luberto, Chiara ^a   Meier, Patrick ^b   Bai, Aiping ^a   Yang, Xiaofeng ^a   Hannun, Yusuf A ^a   Zhou, Daohong ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Apoptosis; Ceramide; D609; Diacylglycerol; Sphingomyelin synthase

Indexed keywords

4 O METHYLPHORBOL 13 ACETATE 12 MYRISTATE; CERAMIDE; CYTOTOXIC AGENT; DIACYLGLYCEROL; GLYCEROL 2 ACETATE 1 OLEATE; SPHINGOMYELIN; TRICYCLO[4.3.0.1]DECAN 9 YL XANTHOGENATE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL LEVEL; CELL LINE; CELL VIABILITY; CYTOTOXICITY; DOSE RESPONSE; ENZYME INHIBITION; HUMAN; HUMAN CELL; INCUBATION TIME; LEUKEMIA CELL; MODULATION; PRIORITY JOURNAL;

EID: 0346992148     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2003.10.001     Document Type: Article

References (32)

1. Rao S.R. Xanthates and Related Compounds. 1971;Marcel Dekker, New York.
2. Amtmann E., Muller K., Knapp A., Sauer G. Reversion of bovine papillomavirus-induced transformation and immortalization by a xanthate compound. Exp. Cell Res. 161:1985;541-550.
3. Amtmann E., Sauer G. Selective killing of tumor cells by xanthates. Cancer Lett. 35:1987;237-244.
4. Porn-Ares M.I., Chow S.C., Slotte J.P., Orrenius S. Induction of apoptosis and potentiation of TNF- and Fas-mediated apoptosis in U937 cells by the xanthogenate compound D609. Exp. Cell Res. 235:1997;48-54.
5. Schick H.D., Amtmann E., Berdel W.E., Danhauser-Riedl S., Reichert A., Steinhauser G., Rastetter J., Sauer G. Antitumoral activity of a xanthate compound: I. Cytotoxicity studies with neoplastic cell lines in vitro. Cancer Lett. 46:1989;143-147.
6. Enomoto A., Suzuki N., Hirano K., Matsumoto Y., Morita A., Sakai K., Koyama H. Involvement of SAPK/JNK pathway in X-ray-induced rapid cell death of human T-cell leukemia cell line MOLT-4. Cancer Lett. 155:2000;137-144.
7. Amtmann E. The antiviral, antitumoural xanthate D609 is a competitive inhibitor of phosphatidylcholine-specific phospholipase C. Drugs Exp. Clin. Res. 22:1996;287-294.
8. Schutze S., Potthoff K., Machleidt T., Berkovic D., Wiegmann K., Kronke M. TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell. 71:1992;765-776.
9. Machleidt T., Kramer B., Adam D., Neumann B., Schutze S., Wiegmann K., Kronke M. Function of the p55 tumor necrosis factor receptor "death domain" mediated by phosphatidylcholine-specific phospholipase C. J. Exp. Med. 184:1996;725-733.
10. Schutze S., Berkovic D., Tomsing O., Unger C., Kronke M. Tumor necrosis factor induces rapid production of 1′2′diacylglycerol by a phosphatidylcholine-specific phospholipase C. J. Exp. Med. 174:1991;975-988.
11. Muller-Decker K., Doppler C., Amtmann E., Sauer G. Interruption of growth signal transduction by an antiviral and antitumoral xanthate compound. Exp. Cell Res. 177:1988;295-302.
12. Muller-Decker K. Interruption of TPA-induced signals by an antiviral and antitumoral xanthate compound: inhibition of a phospholipase C-type reaction. Biochem. Biophys. Res. Commun. 162:1989;198-205.
13. Luberto C., Hannun Y.A. Sphingomyelin synthase, a potential regulator of intracellular levels of ceramide and diacylglycerol during SV40 transformation. Does sphingomyelin synthase account for the putative phosphatidylcholine- specific phospholipase C? J. Biol. Chem. 273:1998;14550-14559.
14. Luberto C., Yoo D.S., Suidan H.S., Bartoli G.M., Hannun Y.A. Differential effects of sphingomyelin hydrolysis and resynthesis on the activation of NF-kappa B in normal and SV40-transformed human fibroblasts. J. Biol. Chem. 275:2000;14760-14766.
15. Riboni L., Viani P., Bassi R., Giussani P., Tettamanti G. Basic fibroblast growth factor-induced proliferation of primary astrocytes. Evidence for the involvement of sphingomyelin biosynthesis. J. Biol. Chem. 276:2001;12797-12804.
16. Miro-Obradors M.J., Osada J., Aylagas H., Sanchez-Vegazo I., Palacios-Alaiz E. Microsomal sphingomyelin accumulation in thioacetamide- injured regenerating rat liver: involvement of sphingomyelin synthase activity. Carcinogenesis. 14:1993;941-946.
17. Bjorkoy G., Perander M., Overvatn A., Johansen T. Reversion of Ras- and phosphatidylcholine-hydrolyzing phospholipase C-mediated transformation of NIH 3T3 cells by a dominant interfering mutant of protein kinase C lambda is accompanied by the loss of constitutive nuclear mitogen-activated protein kinase/extracellular signal-regulated kinase activity. J. Biol. Chem. 272:1997;11557-11565.
18. Cheng J., Weber J.D., Baldassare J.J., Raben D.M. Ablation of Go alpha-subunit results in a transformed phenotype and constitutively active phosphatidylcholine-specific phospholipase C. J. Biol. Chem. 272:1997;17312-17319.
19. Johansen T., Bjorkoy G., Overvatn A., Diaz-Meco M.T., Traavik T., Moscat J. NIH 3T3 cells stably transfected with the gene encoding phosphatidylcholine- hydrolyzing phospholipase C from Bacillus cereus acquire a transformed phenotype. Mol. Cell. Biol. 14:1994;646-654.
20. Carter C.A. Protein kinase C as a drug target: implications for drug or diet prevention and treatment of cancer. Curr. Drug Targets. 1:2000;163-183.
21. Hofmann J. Modulation of protein kinase C in antitumor treatment. Rev. Physiol., Biochem. Pharmacol. 142:2001;1-96.
22. Claus R., Russwurm S., Meisner M., Kinscherf R., Deigner H.P. Modulation of the ceramide level, a novel therapeutic concept? Curr. Drug Targets. 1:2000;185-205.
23. Hannun Y.A., Luberto C., Argraves K.M. Enzymes of sphingolipid metabolism: from modular to integrative signaling. Biochemistry. 40:2001;4893-4903.
24. Kolesnick R. The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J. Clin. Invest. 110:2002;3-8.
25. Senchenkov A., Litvak D.A., Cabot M.C. Targeting ceramide metabolism - A strategy for overcoming drug resistance. J. Natl. Cancer Inst. 93:2001;347-357.
26. Hansen M.B., Nielsen S.E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods. 119:1989;203-210.
27. Darzynkiewicz Z., Bedner E. Analysis of apoptotic cells by flow and laser scanning cytometry. Methods Enzymol. 322:2000;18-39.
28. Majno G., Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am. J. Pathol. 146:1995;3-15.
29. Chmura S.J., Nodzenski E., Crane M.A., Virudachalam S., Hallahan D.E., Weichselbaum R.R., Quintans J. Cross-talk between ceramide and PKC activity in the control of apoptosis in WEHI-231. Adv. Exp. Med. Biol. 406:1996;39-55.
30. Shin H.J., Gye M.H., Chung K.H., Yoo B.S. Activity of protein kinase C modulates the apoptosis induced by polychlorinated biphenyls in human leukemic HL-60 cells. Toxicol. Lett. 135:2002;25-31.
31. Amtmann E., Sauer G. Tumor necrosis factor induces necrosis of human carcinoma xenografts in the presence of tricyclodecan-9-yl-xanthogenate and lauric acid. Int. J. Cancer. 45:1990;1113-1118.
32. Bettaieb A., Plo I., Mansat-De Mas V., Quillet-Mary A., Levade T., Laurent G., Jaffrezou J.P. Daunorubicin- and mitoxantrone-triggered phosphatidylcholine hydrolysis: implication in drug-induced ceramide generation and apoptosis. Mol. Pharmacol. 55:1999;118-125.